{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-308803","form_type":"8-K","ticker":"LNTH","cik":"0001521036","company_name":"Lantheus Holdings, Inc.","filed_at":"2022-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.963701+00:00","generated_at":"2026-06-21T01:44:13.958073+00:00","sec_items":["2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Lantheus closes strategic collaboration & license agreements with POINT Biopharma for PNT-2002 and PNT-2003","bullets":["Paid $250M upfront for PNT-2002 (prostate cancer therapy); $10M upfront for PNT-2003 (neuroendocrine tumor therapy).","Potential regulatory milestones up to $281M (PNT-2002) and $34.5M (PNT-2003); sales milestones up to $1.28B and $275M, respectively.","PNT-2002 royalties: 20% after $500M cumulative gross profit; PNT-2003 royalties: 15% of net sales.","Agreements became effective Dec 20, 2022, after HSR waiting period expired.","Lantheus will develop and commercialize both candidates worldwide except certain Asian countries."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-308803","json":"https://secwatch.observer/filing/0001193125-22-308803.json","markdown":"https://secwatch.observer/filing/0001193125-22-308803.md","text":"https://secwatch.observer/filing/0001193125-22-308803.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521036/000119312522308803/0001193125-22-308803-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521036/000119312522308803/d435614d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T01:44:13.958073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}